Helix BioMedix Statistics
Total Valuation
Helix BioMedix has a market cap or net worth of 1.61 million.
| Market Cap | 1.61M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Helix BioMedix has 224,709 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 224,709 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33
| Current Ratio | 2.33 |
| Quick Ratio | 1.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.46 |
Financial Efficiency
Return on equity (ROE) is -122.53% and return on invested capital (ROIC) is -71.83%.
| Return on Equity (ROE) | -122.53% |
| Return on Assets (ROA) | -59.00% |
| Return on Invested Capital (ROIC) | -71.83% |
| Return on Capital Employed (ROCE) | -204.98% |
| Revenue Per Employee | 258,239 |
| Profits Per Employee | -322,959 |
| Employee Count | 8 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.14% in the last 52 weeks. The beta is 0.48, so Helix BioMedix's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -69.14% |
| 50-Day Moving Average | 22.53 |
| 200-Day Moving Average | 38.52 |
| Relative Strength Index (RSI) | 20.09 |
| Average Volume (20 Days) | 233 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, Helix BioMedix had revenue of 2.07 million and -2.58 million in losses. Loss per share was -15.59.
| Revenue | 2.07M |
| Gross Profit | 1.42M |
| Operating Income | -2.42M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -2.33M |
| EBIT | -2.42M |
| Loss Per Share | -15.59 |
Balance Sheet
The company has 216,534 in cash and n/a in debt, giving a net cash position of 216,534 or 0.96 per share.
| Cash & Cash Equivalents | 216,534 |
| Total Debt | n/a |
| Net Cash | 216,534 |
| Net Cash Per Share | 0.96 |
| Equity (Book Value) | 1.15M |
| Book Value Per Share | 6.94 |
| Working Capital | 690,402 |
Cash Flow
In the last 12 months, operating cash flow was -1.82 million and capital expenditures -10,731, giving a free cash flow of -1.83 million.
| Operating Cash Flow | -1.82M |
| Capital Expenditures | -10,731 |
| Free Cash Flow | -1.83M |
| FCF Per Share | -8.14 |
Margins
Gross margin is 68.96%, with operating and profit margins of -117.30% and -125.06%.
| Gross Margin | 68.96% |
| Operating Margin | -117.30% |
| Pretax Margin | -125.06% |
| Profit Margin | -125.06% |
| EBITDA Margin | -112.72% |
| EBIT Margin | -117.30% |
| FCF Margin | n/a |
Dividends & Yields
Helix BioMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.06% |
| Shareholder Yield | -10.06% |
| Earnings Yield | -160.14% |
| FCF Yield | -113.41% |
Stock Splits
The last stock split was on January 3, 2013. It was a reverse split with a ratio of 0.0033333.
| Last Split Date | Jan 3, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.0033333 |
Scores
Helix BioMedix has an Altman Z-Score of -27.38. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.38 |
| Piotroski F-Score | n/a |